Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+

Authors: Joshua C Doloff, Ting Su, David J Waxman

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Cytochrome P450-based suicide gene therapy for cancer using prodrugs such as cyclophosphamide (CPA) increases anti-tumor activity, both directly and via a bystander killing mechanism. Bystander cell killing is essential for the clinical success of this treatment strategy, given the difficulty of achieving 100% efficient gene delivery in vivo using current technologies. Previous studies have shown that the pan-caspase inhibitor p35 significantly increases CPA-induced bystander killing by tumor cells that stably express P450 enzyme CYP2B6 (Schwartz et al, (2002) Cancer Res. 62: 6928-37).

Methods

To further develop this approach, we constructed and characterized a replication-defective adenovirus, Adeno-2B6/p35, which expresses p35 in combination with CYP2B6 and its electron transfer partner, P450 reductase.

Results

The expression of p35 in Adeno-2B6/p35-infected tumor cells inhibited caspase activation, delaying the death of the CYP2B6 "factory" cells that produce active CPA metabolites, and increased bystander tumor cell killing compared to that achieved in the absence of p35. Tumor cells infected with Adeno-2B6/p35 were readily killed by cisplatin and doxorubicin, indicating that p35 expression is not associated with acquisition of general drug resistance. Finally, p35 did not inhibit viral release when the replication-competent adenovirus ONYX-017 was used as a helper virus to facilitate co-replication and spread of Adeno-2B6/p35 and further increase CPA-induced bystander cell killing.

Conclusions

The introduction of p35 into gene therapeutic regimens constitutes an effective approach to increase bystander killing by cytochrome P450 gene therapy. This strategy may also be used to enhance other bystander cytotoxic therapies, including those involving the production of tumor cell toxic protein products.
Appendix
Available only for authorised users
Literature
1.
Altaner C: Prodrug cancer gene therapy. Cancer Lett. 2008, 270 (2): 191-201. 10.1016/j.canlet.2008.04.023.CrossRefPubMed
2.
Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Chen P, Marais R, Springer CJ: Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer research. 2007, 67 (10): 4949-4955. 10.1158/0008-5472.CAN-07-0297.CrossRefPubMed
3.
Stubdal H, Perin N, Lemmon M, Holman P, Bauzon M, Potter PM, Danks MK, Fattaey A, Dubensky T, Johnson L: A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer research. 2003, 63 (20): 6900-6908.PubMed
4.
Jounaidi Y, Doloff JC, Waxman DJ: Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets. 2007, 7 (3): 285-301. 10.2174/156800907780618301.CrossRefPubMedPubMedCentral
5.
Dachs GU, Tupper J, Tozer GM: From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs. 2005, 16 (4): 349-359. 10.1097/00001813-200504000-00001.CrossRefPubMed
6.
Both GW: Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther. 2009, 11 (4): 421-432.PubMed
7.
Portsmouth D, Hlavaty J, Renner M: Suicide genes for cancer therapy. Mol Aspects Med. 2007, 28 (1): 4-41. 10.1016/j.mam.2006.12.001.CrossRefPubMed
8.
Chen L, Waxman DJ: Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des. 2002, 8 (15): 1405-1416. 10.2174/1381612023394566.CrossRefPubMed
9.
Baldwin A, Huang Z, Jounaidi Y, Waxman DJ: Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Archives of biochemistry and biophysics. 2003, 409 (1): 197-206. 10.1016/S0003-9861(02)00453-8.CrossRefPubMed
10.
Chang TK, Weber GF, Crespi CL, Waxman DJ: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer research. 1993, 53 (23): 5629-5637.PubMed
11.
Huang Z, Roy P, Waxman DJ: Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol. 2000, 59 (8): 961-972. 10.1016/S0006-2952(99)00410-4.CrossRefPubMed
12.
Lu H, Chen CS, Waxman DJ: Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Ther. 2009, 16 (5): 393-404. 10.1038/cgt.2008.93.CrossRefPubMed
13.
Yang Y, Wang JS, Zhang W, Yuan J, Yang M, Fang Q: Study on mesenchymal stem cells mediated enzyme-prodrug gene CYP1A2 targeting anti-tumor effect. Zhonghua Xue Ye Xue Za Zhi. 2009, 30 (10): 667-671.PubMed
14.
Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, Gibson R, Makris A, Talbot DC, Steiner J, et al: Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res. 2005, 11 (4): 1512-1520. 10.1158/1078-0432.CCR-04-0155.CrossRefPubMed
15.
Chen L, Waxman DJ, Chen D, Kufe DW: Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer research. 1996, 56 (6): 1331-1340.PubMed
16.
Pawlik TM, Nakamura H, Mullen JT, Kasuya H, Yoon SS, Chandrasekhar S, Chiocca EA, Tanabe KK: Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer. 2002, 95 (5): 1171-1181. 10.1002/cncr.10776.CrossRefPubMed
17.
Salmons B, Lohr M, Gunzburg WH: Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial. J Gastroenterol. 2003, 38 (Suppl 15): 78-84.PubMed
18.
Clarke L, Waxman DJ: Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer research. 1989, 49 (9): 2344-2350.PubMed
19.
Chen CS, Lin JT, Goss KA, He YA, Halpert JR, Waxman DJ: Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Molecular pharmacology. 2004, 65 (5): 1278-1285. 10.1124/mol.65.5.1278.CrossRefPubMed
20.
Jounaidi Y, Chen CS, Veal GJ, Waxman DJ: Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol Cancer Ther. 2006, 5 (3): 541-555. 10.1158/1535-7163.MCT-05-0321.CrossRefPubMed
21.
McKeown SR, Ward C, Robson T: Gene-directed enzyme prodrug therapy: a current assessment. Curr Opin Mol Ther. 2004, 6 (4): 421-435.PubMed
22.
Roy P, Waxman DJ: Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro. 2006, 20 (2): 176-186. 10.1016/j.tiv.2005.06.046.CrossRefPubMed
23.
Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV: Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules. 2009, 14 (11): 4517-4545. 10.3390/molecules14114517.CrossRefPubMed
24.
Jounaidi Y, Waxman DJ: Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer research. 2004, 64 (1): 292-303. 10.1158/0008-5472.CAN-03-1798.CrossRefPubMed
25.
McCormick F: Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther. 2003, 2 (4 Suppl 1): S157-160.PubMed
26.
Waxman DJ, Schwartz PS: Harnessing apoptosis for improved anticancer gene therapy. Cancer research. 2003, 63 (24): 8563-8572.PubMed
27.
Clem RJ, Fechheimer M, Miller LK: Prevention of apoptosis by a baculovirus gene during infection of insect cells. Science. 1991, 254 (5036): 1388-1390. 10.1126/science.1962198.CrossRefPubMed
28.
Stennicke HR, Ryan CA, Salvesen GS: Reprieval from execution: the molecular basis of caspase inhibition. Trends Biochem Sci. 2002, 27 (2): 94-101. 10.1016/S0968-0004(01)02045-X.CrossRefPubMed
29.
Schwartz PS, Chen CS, Waxman DJ: Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. Cancer research. 2002, 62 (23): 6928-6937.PubMed
30.
Schwartz PS, Chen CS, Waxman DJ: Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Cancer Gene Ther. 2003, 10 (8): 571-582. 10.1038/sj.cgt.7700601.CrossRefPubMed
31.
Bauerschmitz GJ, Barker SD, Hemminki A: Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol. 2002, 21 (6): 1161-1174.PubMed
32.
Everts B, van der Poel HG: Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005, 12 (2): 141-161. 10.1038/sj.cgt.7700771.CrossRefPubMed
33.
Schwartz PS, Waxman DJ: Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Molecular pharmacology. 2001, 60 (6): 1268-1279.PubMed
34.
Abou El Hassan MA, van der Meulen-Muileman I, Abbas S, Kruyt FA: Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol. 2004, 78 (22): 12243-12251. 10.1128/JVI.78.22.12243-12251.2004.CrossRefPubMedPubMedCentral
35.
Subramanian T, Vijayalingam S, Chinnadurai G: Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol. 2006, 80 (4): 2000-2012. 10.1128/JVI.80.4.2000-2012.2006.CrossRefPubMedPubMedCentral
36.
Hedley SJ, Chen J, Mountz JD, Li J, Curiel DT, Korokhov N, Kovesdi I: Targeted and shielded adenovectors for cancer therapy. Cancer Immunol Immunother. 2006, 55 (11): 1412-1419. 10.1007/s00262-006-0158-2.CrossRefPubMed
37.
O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE: PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999, 10 (8): 1349-1358. 10.1089/10430349950018021.CrossRefPubMed
Metadata
Title
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+
Authors
Joshua C Doloff
Ting Su
David J Waxman
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-487

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer

Research article

Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands

Research article

Association between the Cytotoxic T-Lymphocyte Antigen 4 +49G > A polymorphism and cancer risk: a meta-analysis

Research article

Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins

Research article

Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells

Research article

Polymorphisms in regulatory regions of Cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits